Cipla to market Novartis, and J & J ’s products, while Alkem partners Dong A of South Korea

Alkem is bringing in a fresh brand. Evogliptin has been approved in South Korea and the company is waiting for an approval from the USFDA authorities for its North American launch.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news